Please assess the completion status of the following clinical trial:

Trial Title: Doxycycline for COPD in HIV-Infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Documented HIV infection~2. CD4 cell count greater than 200 cells/mm3~3. HIV RNA less than 400 copies/ml~4. Stable antiretroviral therapy for greater than or equal to 12 weeks~5. Fulfills GOLD definition for COPD (post-bronchodilator FEV1/FVC less than 0.7) and/or has radiographic evidence of emphysema~6. Current or history of smoking with minimum 3 pack-year history~7. ALT and AST less than 3 x upper limit of normal~8. For women of childbearing potential: willingness to use 2 forms of birth control~9. Subjects on therapy for COPD must be on stable therapy for at least 4 weeks~Exclusion Criteria:~1. Pulmonary infection, COPD exacerbation, or acute opportunistic infection within 30 days of entry~2. Conditions associated with increased sedation of bronchoscopy risk, including but not limited to Gold class 3 or 4 COPD, requirement for home oxygen, hypercapneic respiratory failure, poorly controlled hypertension~3. Known allergy/intolerance to doxycycline, atropine, or any local anesthetic~4. Inability to provide informed consent~5. Pregnant or lactating women~6. Men must agree not to attempt to make a woman pregnant or participate in sperm donation during the study and for 6 weeks after discontinuing the drug~7. End stage renal disease~8. Cirrhosis~9. INR greater than 1.4~10. Platelets less than 80,000~11. Any condition including active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements or increase the risk of bronchoscopy~12. Active or planned participation in any other clinical trial or observational study without prior approval from the PI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Doxycycline (Type: ACTIVE_COMPARATOR): 100 mg twice daily (BID orally) x 24 weeks
- Placebo (sugar pill) (Type: PLACEBO_COMPARATOR): 100 mg twice daily (BID orally) x 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).